




(a)




Vancomycin (1)

Teicoplanin A₂-2 (2)


(b) Semisynthetic



Telavancin (3)



Dalbavancin (4)



Oritavancin (5)

Figure 4.1 (a) Natural and (b) semisynthetic glycopeptide antibiotics approved for use in humans.

its association with the transfer of vancomycin resistance to *Enterococcus faecium* (Bager et al. 1997). Later, a newer generation of semisynthetic derivatives of glycopeptide antibiotics, telavancin, dalbavancin, and oritavancin (Figure 4.1b), was approved for clinical use (Table 4.1). However, these are yet to be approved for the treatment of vancomycin-resistant infections. The clinically relevant glycopeptides and their mechanisms of action have been described in detail herein.